Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Taletrectinib | C23H24FN5O | CID 72202474 - PubChem
Taletrectinib is a Highly Selective ROS1/NTRK Kinase Inhibitor for ...
Taletrectinib (DS-6051b) | ROS1 inhibitor | CAS 1505515-69-4 | Selleck
Taletrectinib | ROS Kinase | ROS | Trk receptor | TargetMol
Taletrectinib free base (DS-6051b free base) | ROS1/NTRK Inhibitor ...
Taletrectinib is a Synthetic ROS1/NTRK Inhibitor for The Research of ...
FDA approves taletrectinib for ROS1 -positive non-small cell lung cancer
FDA approves taletrectinib for ROS1-positive advanced non-small cell ...
Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST | Journal of ...
ELCC 2023: Updated Efficacy and Safety of Taletrectinib in Patients ...
Taletrectinib free base | ROS Kinase | TargetMol
FDA Approves Taletrectinib for ROS1-Positive NSCLC Treatment
Congratulations! FAB Supports ROS1 Inhibitor Taletrectinib in Securing ...
Full article: TRUST-II: a global phase II study of taletrectinib in ...
FDA Approves Taletrectinib for Lung Cancer Subtype - Oncology Central
NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC | OncLive
FDA Approves Taletrectinib in ROS1+ NSCLC
Taletrectinib Shows Promising Results in Patients with ROS1-Positive ...
NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC
Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer
NCCN Adds Taletrectinib to ROS1+ NSCLC Recommendations
Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC ...
Taletrectinib (DS-6051b; AB-106; IBI-344) | CAS 1505515-69-4 | AbMole ...
Taletrectinib Approved for ROS1-Positive Non–Small Cell Lung Cancer ...
Study of Taletrectinib for ROS1-Positive NSCLC Doses First Patient
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
Taletrectinib | C29H34FN5O5 | CID 72694302 - PubChem
Taletrectinib | 1505514-27-1 | Reference standards | Alsachim
Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST - PMC
Dr Liu on Updated Efficacy and Safety Data With Taletrectinib in ROS1 ...
FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer ...
FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer
Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non ...
Taletrectinib Overview - Active Ingredient - RxReasoner
Taletrectinib Approved for ROS1-Positive NSCLC
Taletrectinib (Ibtrozi): What Patients Should Know About in 2025 ...
Rami Manochakian: FDA Approves Taletrectinib for ROS1-Positive Non ...
FDA Grants Taletrectinib Priority Review for Advanced ROS1+ NSCLC
Taletrectinib Continues to Demonstrate High Clinical Activity in ...
Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in ...
Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ...
Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated ...
Treating Rare Lung Cancer (ROS-1 Positive NSCLC) With Taletrectinib ...
Taletrectinib | ROS | Trk receptor | TargetMol
DailyMed - IBTROZI- taletrectinib capsule
Taletrectinib Data Published as FDA Weighs Approval for ROS1+ NSCLC
Nuvation Bio's Taletrectinib NDA for ROS1+ NSCLC Receives FDA Priority ...
Taletrectinib (Ibtrozi) door de FDA goedgekeurd voor ROS1-positieve ...
Innovent Biologics' Taletrectinib Wins NMPA Approval for ROS1+ NSCLC ...
Taletrectinib Wins Japanese Approval for ROS1+ Advanced NSCLC | OncLive
Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC
Taletrectinib 在ROS1阳性非小细胞肺癌中展现持久疗效：FDA批准的突破性靶向治疗 - MedFind
AnHeart and Innovent enter taletrectinib licensing deal in Greater China
Innovent's Breakthrough in Lung Cancer Treatment: Taletrectinib Shows ...
FDA Accepts for Priority Review Nuvation Bio’s NDA for Taletrectinib to ...
NCCN Guidelines Add Taletrectinib as Preferred Treatment for ROS1+ Lung ...
Ibtrozi Approved for Advanced ROS1-Positive NSCLC - Pulmonology Advisor
第二代ROS1/NTRK双靶点抑制剂,Taletrectinib(DS-6051b)数据公布,AB-106临床试验招募中-无癌家园
DS-6051b (Taletrectinib, AB-106, IBI-344) | ROS1/NTRK inhibitor ...
2021CSCO大会|同济大学附属上海市肺科医院周彩存教授:ROS1/NTRK双靶点抑制剂Taletrectinib初步研究结果出炉-无癌家园
Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer ...
DS-6051b(Taletrectinib/他来替尼/AB-106)中国数据出炉,90%以上患者病灶显著缩小,中国患者再迎肺癌新药_全球肿瘤医生网
IBTROZI™ (Taletrectinib), FDA-Approved Treatment, Available at ...
Taletrectinib: First Approval | Drugs
Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 ...
FDA Approves Ibtrozi (taletrectinib) for Advanced ROS1-Positive Non ...
ROS1阳性肺癌新希望：Taletrectinib靶向药TRUST研究揭示突破性疗效与安全性 - MedFind
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 ...
Nuvation Bio's Ibtrozi (taletrectinib) Now Approved by FDA for NSCLC
Listen to the New Episode of Lung Cancer Considered on the FDA Approval ...
Taletrectinib: A New Advance in ROS1-Mutant NSCLC | Targeted Oncology ...
Taletrectinib（DS-6051b / AB-106）_肺癌_抗癌药物_全球肿瘤医生网
ROS1/NTRK靶向新药Taletrectinib（AB-106）治疗肺癌疗效优异！-印塔健康官网
新型ROS1靶向药Taletrectinib获FDA批准：非小细胞肺癌治疗新突破 - MedFind
Ibtrozi: Uses, Dosage, Side Effects & Warnings - Drugs.com
FDA Novel Drug Approvals 2025 Update | Precision Oncology, Rare ...
Nuvation Bio Announces Expanded Access Program in the U.S. for ...
继瑞普替尼之后，新型ROS1抑制剂：Taletrectinib（他雷替尼）中国获批上市！ - 知乎
AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 ...
These highlights do not include all the information needed to use ...
ROS1肺癌控制率超90%！靶向新藥Taletrectinib一線療效強勁 - HKUOC
2024年12月20日国家药监局批准二酸他雷替尼胶囊(Taletrectinib、达伯乐、AB-106)用于经ROS1-TKI治疗后进展的 ...
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI ...
Innovent Announces Second New Drug Application of DOVBLERON ...
J Clin Oncol | Taletrectinib：对抗G2032R突变的强效ROS1抑制剂，临床研究显现持续疗效_腾讯新闻
新一代同时靶向ROS1和NTRK的双靶点药物他雷替尼(Taletrectinib、AB106)在中国获批突破性疗法_全球肿瘤医生网
Innovent Reports the NMPA’s Approval of Dovbleron (Taletrectinib ...
上市在即！ROS1/NTRK靶向药他雷替尼（Taletrectinib）说明书！
ROS1/NTRK靶向新药Taletrectinib/他雷替尼说明书-适应症-上市，可以克服克唑替尼耐药，并穿透血脑屏障 - 知乎
